全文获取类型
收费全文 | 6988篇 |
免费 | 645篇 |
国内免费 | 17篇 |
专业分类
耳鼻咽喉 | 91篇 |
儿科学 | 234篇 |
妇产科学 | 102篇 |
基础医学 | 904篇 |
口腔科学 | 121篇 |
临床医学 | 933篇 |
内科学 | 1191篇 |
皮肤病学 | 84篇 |
神经病学 | 868篇 |
特种医学 | 286篇 |
外国民族医学 | 1篇 |
外科学 | 926篇 |
综合类 | 160篇 |
一般理论 | 7篇 |
预防医学 | 899篇 |
眼科学 | 151篇 |
药学 | 356篇 |
中国医学 | 6篇 |
肿瘤学 | 330篇 |
出版年
2021年 | 98篇 |
2020年 | 83篇 |
2019年 | 109篇 |
2018年 | 146篇 |
2017年 | 110篇 |
2016年 | 92篇 |
2015年 | 82篇 |
2014年 | 156篇 |
2013年 | 214篇 |
2012年 | 381篇 |
2011年 | 338篇 |
2010年 | 175篇 |
2009年 | 164篇 |
2008年 | 288篇 |
2007年 | 326篇 |
2006年 | 275篇 |
2005年 | 310篇 |
2004年 | 324篇 |
2003年 | 308篇 |
2002年 | 236篇 |
2001年 | 221篇 |
2000年 | 229篇 |
1999年 | 187篇 |
1998年 | 80篇 |
1997年 | 62篇 |
1996年 | 53篇 |
1995年 | 115篇 |
1994年 | 147篇 |
1993年 | 122篇 |
1992年 | 199篇 |
1991年 | 171篇 |
1990年 | 137篇 |
1989年 | 162篇 |
1988年 | 152篇 |
1987年 | 113篇 |
1986年 | 117篇 |
1985年 | 118篇 |
1984年 | 92篇 |
1983年 | 80篇 |
1982年 | 53篇 |
1979年 | 76篇 |
1978年 | 43篇 |
1977年 | 49篇 |
1976年 | 41篇 |
1974年 | 53篇 |
1973年 | 61篇 |
1972年 | 55篇 |
1971年 | 42篇 |
1969年 | 48篇 |
1968年 | 37篇 |
排序方式: 共有7650条查询结果,搜索用时 46 毫秒
1.
Jeffrey I. Campbell Angella Musiimenta Bridget Burns Sylvia Natukunda Nicholas Musinguzi Jessica E. Haberer 《AIDS care》2019,31(6):761-766
Novel monitoring technologies in HIV research, such as electronic adherence monitors (EAMs), have changed the nature of researcher-participant interactions. Yet little is known about how EAMs and the resulting interaction between researchers and participants affect research participation and the data gathered. We interviewed participants and research assistants (RAs) in an observational cohort study involving EAMs for HIV antiretroviral therapy (ART) in Uganda. We qualitatively explored interviewees’ views about ethical issues surrounding EAMs and assessed data with conventional and directed content analysis. Participants valued their relationships with RAs and were preoccupied with RAs’ perceptions of them. Participants were pleased when the EAM revealed regular adherence, and annoyed when it revealed non-adherence that contradicted self-reported pill-taking behavior. For many, the desire to maintain a good impression incentivized adherence. But some sought to creatively conceal non-adherence, or refused to use the EAM to avoid revealing non-adherence to RAs. These findings show that participants’ perceptions of the study staff's perceptions of them affected the experience of being monitored, study participation, and ultimately the data gathered in the study. Investigators in monitoring-based research should be aware that social interactions between participants and study staff could affect both the practical and ethical conduct of that research. 相似文献
2.
3.
4.
Riccardo Zuccarino Valeria Prada Isabella Moroni Emanuela Pagliano Maria Foscan Giulia Robbiano Chiara Pisciotta Kayla Cornett Rosemary Shy Angelo Schenone Davide Pareyson Michael Shy Joshua Burns 《Journal of the peripheral nervous system : JPNS》2020,25(2):138-142
The Charcot‐Marie‐Tooth disease Pediatric Scale (CMTPedS) is a Rasch‐built clinical outcome measure of disease severity. It is valid, reliable, and responsive to change for children and adolescents aged 3 to 20 years. The aim of this study was to translate and validate an Italian version of the CMTPedS using a validated framework of transcultural adaptation. The CMTPedS (Italian) was translated and culturally adapted from source into Italian by two experts in CMT with good English language proficiency. The two translations were reviewed by a panel of experts in CMT. The agreed provisional version was back translated into English by a professional translator. The definitive Italian version was developed during a consensus teleconference by the same panel. CMT patients were assessed with the final version of the outcome measure and a subset had a second assessment after 2 weeks to evaluate test‐retest reliability. Seventeen patients with CMT aged 5 to 20 years (eight female) were evaluated with the CMTPedS (Italian), and test‐retest was performed in three patients. The CMTPedS (Italian) showed a high test‐retest reliability. No patient had difficulty in completing the scale. The instructions for the different items were clearly understood by clinicians and therefore the administration of the outcome measure was straight forward and easily understood by the children assessed. The CMTPedS (Italian) will be used for clinical follow‐up and in clinical research studies in the Italian population. The data is fully comparable to that obtained from the English language version. 相似文献
5.
Emrah Aydn Heather Nolan Jose Luis Peir Patricia Burns Beth Rymeski Foong-Yen Lim 《Pediatric surgery international》2020,36(4):485-491
Primary closure is often inadequate for large congenital diaphragmatic hernia (CDH) and necessitates repair by prosthetic patch or autologous muscle flap. Our aim was to evaluate outcomes of open patch versus flap repair, specifically diaphragmatic reherniation. A retrospective review (IRB #2017-6361) was performed on all CDH patients repaired from 2005 to 2016 at a single academic children’s hospital. Patients were excluded from final analysis if they had primary or minimally invasive repair, expired, or were lost to follow-up. Of 171 patients, 151 (88.3%) survived to discharge, 9 expired after discharge and 11 were lost to follow up, leaving 131 (86.8%) long-term survivors. Median follow-up was 5 years. Open repair was performed in 119 (90.8%) of which 28 (23.5%) underwent primary repair, 34 (28.6%) patch repair, and 57 (47.9%) flap repair. Overall, 6/119 (5%) patients reherniated, 1/28 (3.6%) in the primary group, 3/34 (8.8%) in the patch group, and 2/57 (3.5%) in the flap group. Comparing prosthetic patch to muscle flap repair, there was no significant difference in the number of patients who recurred nor time to reherniation (3 vs. 2, p = 0.295; 5.5 ± 0.00 months vs. 53.75 ± 71.06 months, p = 0.288). One patient in the patch group recurred twice. Both muscle flap and patch repair of large CDH are feasible and durable with a relatively low risk of recurrence. 相似文献
6.
Tejaswini Parlapalle Reddy Usman Khan Ethan Alexander Burns Maen Abdelrahim 《World journal of clinical oncology》2020,11(11):959-967
BACKGROUNDColorectal cancer (CRC) is the third leading cause of cancer-related death in males and females in the United States. Approximately, 20%-22% of patients have metastatic disease at the time of presentation, and 50%-60% will develop metastasis over the course of their disease. Despite advances in systemic therapies, there remains a paucity of effective third- and later-line therapies for patients with ongoing disease progression. However, rechallenging chemo-resistant CRC tumors with previously administered therapies is an emerging concept that may be a life-prolonging option for heavily treated metastatic colorectal cancer (mCRC).CASE SUMMARYA 41-year-old man with no previous medical history initially presented with worsening diffuse abdominal tenderness. Computed tomography was significant for a splenic flexure mass and hepatic lesions concerning for metastatic disease. He underwent a colectomy with anastomosis. Postoperative pathology was diagnostic for moderately to well-differentiated adenocarcinoma (T4bN1bM1a). He received adjuvant 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX), but therapy was discontinued due to the development of atrial fibrillation. Additional workup indicated a carcinoembryonic antigen level of 508.2 ng/mL, and mutational analysis found that the tumor was microsatellite instability-high and KRAS/BRAF wild-type. He was started on irinotecan with oxaliplatin (IROX), and bevacizumab (14 cycles), developed disease progression, was transitioned to FOLFOX and cetuximab, and then eventually three cycles of pembrolizumab. Following disease progression, he was rechallenged with IROX therapy, as he previously responded well to oxaliplatin-based therapy. The IROX rechallenge provided this patient with a ten-month survival benefit, decreased metastatic burden, and marked improvement in his clinical condition.CONCLUSIONRechallenge of previous lines of well-tolerated systemic chemotherapy regimens may be a valuable therapeutic strategy in patients with heavily-treated mCRC. 相似文献
7.
Ahmed Elhassanny Rene Escobedo Daniel Ladin Colin Burns Rukiyah Van Dross 《Oncotarget》2020,11(52):4788
Metastatic melanoma is the most deadly skin neoplasm in the United States. Outcomes for this lethal disease have improved dramatically due to the use of both targeted and immunostimulatory drugs. Immunogenic cell death (ICD) has emerged as another approach for initiating antitumor immunity. ICD is triggered by tumor cells that display damage-associated molecular patterns (DAMPs). These DAMP molecules recruit and activate dendritic cells (DCs) that present tumor-specific antigens to T cells which eliminate neoplastic cells. Interestingly, the expression of DAMP molecules occurs in an endoplasmic reticulum (ER) stress-dependent manner. We have previously shown that ER stress was required for the cytotoxic activity of the endocannabinoid metabolite, 15-deoxy, Δ12,14 prostamide J2 (15dPMJ2). As such, the current study investigates whether 15dPMJ2 induces DAMP signaling in melanoma. In B16F10 cells, 15dPMJ2 caused a significant increase in the cell surface expression of calreticulin (CRT), the release of ATP and the secretion of high-mobility group box 1 (HMGB1), three molecules that serve as surrogate markers of ICD. 15dPMJ2 also stimulated the cell surface expression of the DAMP molecules, heat shock protein 70 (Hsp70) and Hsp90. In addition, the display of CRT and ATP was increased by 15dPMJ2 to a greater extent in tumorigenic compared to non-tumorigenic melanocytes. Consistent with this finding, the activation of bone marrow-derived DCs was upregulated in co-cultures with 15dPMJ2-treated tumor compared to non-tumor melanocytes. Moreover, 15dPMJ2-mediated DAMP exposure and DC activation required the electrophilic cyclopentenone double bond within the structure of 15dPMJ2 and the ER stress pathway. These results demonstrate that 15dPMJ2 is a tumor-selective inducer of DAMP signaling in melanoma. 相似文献
8.
9.
10.
Dave R. Lal Samir K. Gadepalli Cynthia D. Downard Peter C. Minneci Michelle Knezevich Thomas H. Chelius Cooper T. Rapp Deborah Billmire Steven Bruch R. Carland Burns Katherine J. Deans Mary E. Fallat Jason D. Fraser Julia Grabowski Ferdynand Hebel Michael A. Helmrath Ronald B. Hirschl Rashmi Kabre Thomas T. Sato 《Journal of pediatric surgery》2019,54(4):688-692